Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoGen, a developer of antibody-based anticancer therapeutics, has announced that Daniel Junius, currently president and COO, will become president and CEO effective January 1, 2009 in accordance with a succession plan approved by the company's board of directors.
Subscribe to our email newsletter
Mr Junius also has been nominated to join the board, with this nomination to be voted upon at the company’s upcoming annual meeting of shareholders. Mitchel Sayare, currently chairman and CEO, will continue as the chairman of the board and as a director of the company.
Mr Junius joined ImmunoGen in May 2005 as senior vice president of finance and CFO. He was promoted to executive vice president of finance and CFO in July 2006, and then to president and COO earlier in 2008.
Mr Junius said: “ImmunoGen has come a long way under Mitch’s direction, and I look forward to working with the team of talented and dedicated employees here to take the company to the next stage. A key focus will be to continue to accelerate our transition from being primarily a research organization to one with strong, integrated research, clinical, regulatory and manufacturing functions to support our advancing product pipeline.”